Literature DB >> 31245413

Alcohol use in patients with non-alcoholic fatty liver: a tangled web of causality.

Danielle Brandman1, Norah A Terrault1.   

Abstract

Entities:  

Year:  2019        PMID： 31245413      PMCID： PMC6561883          DOI： 10.21037/hbsn.2019.01.07

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  13 in total

1.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Authors:  Eduardo Vilar-Gomez; Luis Calzadilla-Bertot; Vincent Wai-Sun Wong; Marlen Castellanos; Rocio Aller-de la Fuente; Mayada Metwally; Mohammed Eslam; Licet Gonzalez-Fabian; María Alvarez-Quiñones Sanz; Antonio Felix Conde-Martin; Bastiaan De Boer; Duncan McLeod; Anthony Wing Hung Chan; Naga Chalasani; Jacob George; Leon A Adams; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2018-05-05       Impact factor: 22.682

2.  Alcohol, cardiovascular risk, and health: there is a window for benefits.

Authors:  G de Gaetano; A Di Castelnuovo; S Costanzo; M B Donati; L Iacoviello
Journal:  J Thromb Haemost       Date:  2006-05       Impact factor: 5.824

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

Review 5.  Cardiovascular risks and benefits of moderate and heavy alcohol consumption.

Authors:  Joaquim Fernández-Solà
Journal:  Nat Rev Cardiol       Date:  2015-06-23       Impact factor: 32.419

6.  Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.

Authors:  Eduardo Vilar-Gomez; Luis Calzadilla-Bertot; Scott L Friedman; Bienvenido Gra-Oramas; Licet Gonzalez-Fabian; Sacha Lazo-Del Vallin; Moises Diago; Leon A Adams
Journal:  Liver Int       Date:  2017-06-14       Impact factor: 5.828

7.  Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.

Authors:  Veeral Ajmera; Patricia Belt; Laura A Wilson; Ryan M Gill; Rohit Loomba; David E Kleiner; Brent A Neuschwander-Tetri; Norah Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-14       Impact factor: 11.382

8.  Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study.

Authors:  Yoosoo Chang; Yong Kyun Cho; Yejin Kim; Eunju Sung; Jiin Ahn; Hyun-Suk Jung; Kyung Eun Yun; Hocheol Shin; Seungho Ryu
Journal:  Hepatology       Date:  2018-12-26       Impact factor: 17.425

9.  Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Hongyan Ning; Norrina B Allen; Veeral Ajmera; Cora E Lewis; John Jeffrey Carr; Donald M Lloyd-Jones; Norah A Terrault; Juned Siddique
Journal:  Gastroenterology       Date:  2017-08-09       Impact factor: 33.883

10.  Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies.

Authors:  Angela M Wood; Stephen Kaptoge; Adam S Butterworth; Peter Willeit; Samantha Warnakula; Thomas Bolton; Ellie Paige; Dirk S Paul; Michael Sweeting; Stephen Burgess; Steven Bell; William Astle; David Stevens; Albert Koulman; Randi M Selmer; W M Monique Verschuren; Shinichi Sato; Inger Njølstad; Mark Woodward; Veikko Salomaa; Børge G Nordestgaard; Bu B Yeap; Astrid Fletcher; Olle Melander; Lewis H Kuller; Beverley Balkau; Michael Marmot; Wolfgang Koenig; Edoardo Casiglia; Cyrus Cooper; Volker Arndt; Oscar H Franco; Patrik Wennberg; John Gallacher; Agustín Gómez de la Cámara; Henry Völzke; Christina C Dahm; Caroline E Dale; Manuela M Bergmann; Carlos J Crespo; Yvonne T van der Schouw; Rudolf Kaaks; Leon A Simons; Pagona Lagiou; Josje D Schoufour; Jolanda M A Boer; Timothy J Key; Beatriz Rodriguez; Conchi Moreno-Iribas; Karina W Davidson; James O Taylor; Carlotta Sacerdote; Robert B Wallace; J Ramon Quiros; Rosario Tumino; Dan G Blazer; Allan Linneberg; Makoto Daimon; Salvatore Panico; Barbara Howard; Guri Skeie; Timo Strandberg; Elisabete Weiderpass; Paul J Nietert; Bruce M Psaty; Daan Kromhout; Elena Salamanca-Fernandez; Stefan Kiechl; Harlan M Krumholz; Sara Grioni; Domenico Palli; José M Huerta; Jackie Price; Johan Sundström; Larraitz Arriola; Hisatomi Arima; Ruth C Travis; Demosthenes B Panagiotakos; Anna Karakatsani; Antonia Trichopoulou; Tilman Kühn; Diederick E Grobbee; Elizabeth Barrett-Connor; Natasja van Schoor; Heiner Boeing; Kim Overvad; Jussi Kauhanen; Nick Wareham; Claudia Langenberg; Nita Forouhi; Maria Wennberg; Jean-Pierre Després; Mary Cushman; Jackie A Cooper; Carlos J Rodriguez; Masaru Sakurai; Jonathan E Shaw; Matthew Knuiman; Trudy Voortman; Christa Meisinger; Anne Tjønneland; Hermann Brenner; Luigi Palmieri; Jean Dallongeville; Eric J Brunner; Gerd Assmann; Maurizio Trevisan; Richard F Gillum; Ian Ford; Naveed Sattar; Mariana Lazo; Simon G Thompson; Pietro Ferrari; David A Leon; George Davey Smith; Richard Peto; Rod Jackson; Emily Banks; Emanuele Di Angelantonio; John Danesh
Journal:  Lancet       Date:  2018-04-14       Impact factor: 202.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.